EP1487400A2 - Agents cosmetiques - Google Patents

Agents cosmetiques

Info

Publication number
EP1487400A2
EP1487400A2 EP02771566A EP02771566A EP1487400A2 EP 1487400 A2 EP1487400 A2 EP 1487400A2 EP 02771566 A EP02771566 A EP 02771566A EP 02771566 A EP02771566 A EP 02771566A EP 1487400 A2 EP1487400 A2 EP 1487400A2
Authority
EP
European Patent Office
Prior art keywords
acid
esters
composition according
contain
caffeic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02771566A
Other languages
German (de)
English (en)
Inventor
Florence Henry
Philippe Moser
Gilles Pauly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Health and Care Products France SAS
Original Assignee
Cognis France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis France SAS filed Critical Cognis France SAS
Priority to EP02771566A priority Critical patent/EP1487400A2/fr
Publication of EP1487400A2 publication Critical patent/EP1487400A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the invention is in the field of cosmetics and relates to new preparations with an effective amount of esters of caffeic acid.
  • the object of the present invention was therefore to provide new cosmetic preparations which are simultaneously skin-cosmetic and have particular anti-inflammatory properties. Description of the invention
  • the invention relates to cosmetic compositions containing an effective amount of at least one caffeic acid ester.
  • esters of caffeic acid especially mono- and dicafeyl tartaric acid esters, and extracts in which these substances are enriched, meet the stated requirement in an excellent manner.
  • esters of dihydroxycinnamic or caffeic acid can be condensation products with linear or branched, saturated or unsaturated alcohols with 6 to 22 carbon atoms.
  • esters with hydroxy carboxylic acids i.e. the acyl group of caffeic acid forms a compound with the hydroxyl function of hydroxycarboxylic acid.
  • suitable hydroxycarboxylic acids are, in particular, citric acid and particularly preferably tartaric acid. If the hydroxycarboxylic acid has more than one hydroxyl group, the diesters can be used in addition to the monoesters - alone or in a mixture. Therefore, e.g. Monocaffeoyl tartaric acid (caftaric acid, I), dicaffeoyl tartaric acid (chicory acid, II) and mixtures thereof.
  • the agents can contain caffeic acid esters of the formula (III)
  • radicals R are each independently either hydrogen or a hydroxyl group and R 1 is either hydroxyl or the rest of a dicarboxylic acid or a dicarboxylic acid monoester.
  • esters according to formula (III) are preferred in which the aromatic rings each have two hydroxyl groups in the ortho or para position and the radical R on the non-aromatic ring system is also hydroxyl.
  • Typical examples are 3,5-dicaffeoylquinic acid (3,5-DCQA), in which R 1 stands for hydroxyl and l-methoxyoxalyl-3,5-dicaffeoylquinic acid (l-MO-3,5DCQA), in R 1 for the monomethyl terrest of oxalic acid.
  • the agents can also contain free caffeic acid in addition to the caffeic acid esters, the weight ratio of ester to acid typically being in the range from 90:10 to 99: 1.
  • the agents according to the invention can contain the caffeic acid esters in amounts of 0.01 to 5, preferably 0.1 to 2 and in particular 0.5 to 1% by weight.
  • the caffeic acid esters can in principle be of a naturally synthetic nature, extracts from plants or bacteria which contain an effective amount of these substances will be used for economic reasons.
  • Esters in which two moles of caffeic acid are linked to one another via the two hydroxyl groups of one mole of tartaric acid are found particularly frequently in plants of the genus Echinacea, such as, for example, Echinacea purpurea, E. pallida or E.augustifolia.
  • Chicory and green coffee beans are particularly suitable as starting materials, and their extracts are therefore particularly preferred as raw materials.
  • Coffee esters can also be produced biotechnologically, for example from bacteria of the type Baccharis genistelloides or Achyrocline satureiodes.
  • the substances are extracted directly from the aqueous solutions. extraction
  • the extracts can be prepared in a manner known per se, ie for example by aqueous, alcoholic or aqueous-alcoholic extraction of the plants or parts of plants.
  • suitable conventional extraction methods such as maceration, remaceration, digestion, movement maceration, vortex extraction, ultrasound extraction, countercurrent extraction, percolation, repercolation, evacuation (extraction under reduced pressure), diacolation and solid-flow extraction continuous reflux which is carried out in a Soxhlet extractor, which is familiar to the person skilled in the art and in principle all can be used, for the sake of simplicity, for example, on Hager's manual of pharmaceutical practice, (5th edition, vol. 2, pp.
  • Fresh plants or parts of plants can be used as the starting material, but usually dried plants and / or parts of plants are used, which can be mechanically comminuted before extraction. All comminution methods known to the person skilled in the art are suitable here, freeze grinding being mentioned as an example.
  • Organic solvents, water (preferably hot water at a temperature of above 80 ° C. and in particular above 95 ° C.) or mixtures of organic solvents and water, in particular low molecular weight alcohols with more or less high water contents, can be used as solvents for carrying out the extractions become.
  • Extraction with methanol, ethanol, pentane, hexane, heptane, acetone, propylene glycols, polyethylene glycols and ethyl acetate as well as mixtures thereof and their aqueous mixtures is particularly preferred.
  • the extraction is usually carried out at 20 to 100 ° C, preferably at 30 to 90 ° C, in particular at 60 to 80 ° C.
  • the extraction takes place under an inert gas atmosphere to avoid oxidation of the active ingredients of the extract. This is particularly important for extractions at temperatures above 40 ° C.
  • the extraction times are set by the person skilled in the art depending on the starting material, the extraction process, the extraction temperature, the ratio of solvent to raw material, etc.
  • the crude extracts obtained can optionally be subjected to further customary steps, such as purification, concentration and / or decolorization. If desired, the extracts produced in this way can, for example, be subjected to a selective separation of individual undesirable ingredients.
  • the present invention encompasses the knowledge that the extraction conditions and the yields of the final extracts are, according to desired field of application can be selected.
  • the extracts can also serve as starting materials for the production of the above-mentioned pure active ingredients, provided that these cannot be produced more easily and inexpensively by synthetic means. Accordingly, the active substance content in the extracts can be 5 to 100, preferably 50 to 95% by weight.
  • the extracts themselves can be present as aqueous and / or preparations dissolved in organic solvents and as spray-dried or freeze-dried, anhydrous solids.
  • suitable organic solvents in this connection are the aliphatic alcohols having 1 to 6 carbon atoms (eg ethanol), ketones (eg acetone), halogenated hydrocarbons (eg chloroform or methylene chloride), lower esters or polyols (eg glycerol or glycols).
  • aliphatic alcohols having 1 to 6 carbon atoms eg ethanol
  • ketones eg acetone
  • halogenated hydrocarbons eg chloroform or methylene chloride
  • lower esters or polyols eg glycerol or glycols.
  • Another object of the invention relates to the use of esters of coffee for the production of cosmetic preparations, especially skin treatment agents, in which they contain in amounts of 0.01 to 5, preferably 0.1 to 2 and in particular 0.5 to 1 wt .-% could be. Furthermore, the invention also relates to the special use of coffee esters
  • ROS reactive oxygen components
  • the caffeic acid esters can be used to produce cosmetic preparations such as creams, gels, lotions, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, stick preparations, powders or ointments.
  • agents can also be used as further auxiliaries and additives, mild surfactants, oil bodies, emulsifiers, pearlescent waxes, consistency agents, thickeners, superfatting agents, stabilizers, polymers, silicone compounds, fats, waxes, lecithins, phospholipids, biogenic active ingredients, UV light protection factors, antioxidants, deodorants, Antiperspirants, antidandruff agents, film formers, swelling agents, insect repellents, self-tanners, tyrosine inhibitors (depigmenting agents), hydrotropes, solubilizers, preservatives, perfume oils, dyes and the like.
  • Anionic, nonionic, cationic and / or amphoteric or zwitterionic surfactants may be present as surface-active substances, the proportion of which in the compositions is usually about 1 to 70, preferably 5 to 50 and in particular 10 to 30% by weight.
  • anionic surfactants are soaps, finsulfonate alkylbenzenesulfonates, alkanesulfonates, olefinsulfonates, alkyl ether sulfonates, glycerol ether, ⁇ -methyl ester sulfonates, sulfonic fofettTalkren, alkyl sulfates, fatty alcohol ether sulfates, Glycerol ether, Fettklareethersulfa- te, Hydroxymischethersulfate, monoglyceride (ether) sulfates, fatty acid amide (ether) sulfates, mono- and dialkylsulfosuccinates, mono- and dialkylsulfosuccinamates, sulfotriglycerides, amide soaps, ether carboxylic acids and their salts, fatty acid isethionates, fatty acid sarcosinates, fatty acid taurides
  • anionic surfactants contain polyglycol ether chains, they can have a conventional, but preferably a narrow, homolog distribution.
  • Typical examples of nonionic surfactants are fatty alcohol polyglycol ethers, alkylphenol polyglycol ethers, fatty acid polyglycol esters, fatty acid amide polyglycol ethers, fatty amine polyglycol ethers, alkoxylated triglycerides, mixed ethers or mixed formals, optionally partially oxidized alk (en) yl oligoglycosides or especially glucoramide acid vegetable derivatives, fatty acid glucoronic acid protein derivatives, and fatty acid glucoramides Wheat base), polyol fatty acid esters, sugar esters, sorbitan esters, polysorbates and amine oxides.
  • nonionic surfactants contain polyglycol ether chains, they can have a conventional, but preferably a narrow, homolog distribution.
  • cationic surfactants are quaternary ammonium Compounds such as dimethyl distearyl ammonium chloride and ester quats, especially quaternized fatty acid trialkanolamine ester salts.
  • amphoteric or zwitterionic surfactants are alkyl betaines, alkyl amido betaines, aminopropionates, aminoglycinates, imidazolinium betaines and sulfobetaines. The surfactants mentioned are exclusively known compounds.
  • Typical examples of particularly suitable mild, ie particularly skin-compatible, surfactants are fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosines, fatty acid taurides, fatty acid glutamates, ⁇ -olefin sulfonucyl amides, fatty amide carboxylates, ether carboxylic acid fatty acids, amide carboxylate fatty acids, amide carboxylate fatty acids, amide carboxylate fatty acids, amide carboxylate fatty acids and / or protein fatty acid condensates, the latter preferably based on wheat proteins.
  • esters of linear C 6 -C 22 fatty acids with linear or branched C 6 -C 22 fatty alcohols or esters of branched C 5 -C 4 come as oil bodies, for example 13 - carboxylic acids with linear or branched C 6 -C 22 fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl rucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate, cetyl stearate
  • esters of linear C 6 -C 2 fatty acids with branched alcohols in particular 2-ethylhexanol
  • esters of C 8 -C 38 alkyl hydroxy carboxylic acids with linear or branched C 6 -C 22 fatty alcohols cf.
  • esters of linear and / or branched fatty acids with polyhydric alcohols for example propylene glycol, dimer diol or trimer triol
  • polyhydric alcohols for example propylene glycol, dimer diol or trimer triol
  • Guerbet alcohols triglycerides based on C 6 -C ⁇ 0 fatty acids, liquid mono- / di- / triglyceride mixtures
  • esters of C 6 -C 22 fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids especially benzoic acid
  • Esters of C 2 -C 2 -dicarboxylic acids with linear or branched alcohols with 1 to 22 carbon atoms or polyols with 2 to 10 carbon atoms and 2 to 6 hydroxyl groups vegetable oils, branched primary alcohols, substituted cyclohexanes, linear and branched C 6 -C 22 -Fatty alcohol carbonates, such as dicapry
  • Finsolv® TN linear or branched, symmetrical or asymmetrical dialkyl ethers with 6 to 22 carbon atoms per alkyl group, such as dicaprylyl ether (Cetiol® OE), ring opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicones, silicon methicone types, etc.) and / or aliphatic or naphthenic hydrocarbons, such as, for example, squalane, squalene or dialkylcyclohexanes.
  • dicaprylyl ether such as dicaprylyl ether (Cetiol® OE)
  • silicone oils cyclomethicones, silicon methicone types, etc.
  • aliphatic or naphthenic hydrocarbons such as, for example, squalane, squalene or dialkylcyclohexanes.
  • Suitable emulsifiers are nonionic surfactants from at least one of the following groups:
  • Partial esters of polyglycerol (average degree of self-condensation 2 to 8), polyethylene glycol (molecular weight 400 to 5000), trimethylolpropane, pentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) (e.g.
  • cellulose saturated and / or unsaturated, linear or branched fatty acids with 12 to 22 carbon atoms and / or hydroxycarboxylic acids with 3 to 18 carbon atoms and their adducts with 1 to 30 mol ethylene oxide; > Mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol according to DE 1165574 PS and / or mixed esters of fatty acids with 6 to 22 carbon atoms, methyl glucose and polyols, preferably glycerol or polyglycerol.
  • Block copolymers e.g. Polyethylene glycol 30 dipolyhydroxystearate;
  • Polymer emulsifiers e.g. Pemulen types (TR-1, TR-2) from Goodrich;
  • the adducts of ethylene oxide and / or of propylene oxide with fatty alcohols, fatty acids, alkylphenols or with castor oil are known, commercially available products. These are mixtures of homologs whose average degree of alkoxylation is the ratio of the amounts of ethylene oxide and / or propylene oxide and Substrate with which the addition reaction is carried out corresponds.
  • C i2 / i 8 - fatty acid monoesters and diesters of adducts of ethylene oxide with glycerol are known from DE 2024051 PS as refatting agents for cosmetic preparations.
  • Alkyl and / or alkenyl oligoglycosides their preparation and their use are known from the prior art. They are produced in particular by reacting glucose or oligosaccharides with primary alcohols with 8 to 18 carbon atoms.
  • glycoside residue both monoglycosides in which a cyclic sugar residue is glycosidically bonded to the fatty alcohol and oligomeric glycosides with a degree of oligomerization of up to about 8 are suitable.
  • the degree of oligomerization is a statistical mean value which is based on a homolog distribution customary for such technical products. > Partial glycerides
  • Suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid, Isostearinklarediglycerid, oleic acid monoglyceride, oleic acid diglyceride, Ricinolklaremoglycerid, Ricinolklarediglycerid, Linolklaremonoglycerid, Linolklarediglycerid, Linolenchuremonoglycerid, linolenic acid diglyceride, Erucaklaremonoglycerid, Erucaklakladiglycerid, Weinklaremonoglycerid, Weinkladodiglycerid, Citronenklamonoglycerid, Citronendiglycerid, ⁇ pfelklaklamo- noglycerid, Apfelklarochrediglycerid and their technical mixtures, which may still contain small amounts of triglyceride from the manufacturing process. Addition products of 1 to 30, preferably
  • sorbitan sorbitan, sorbitan sesquiisostearate, sorbitan come diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan dioleate, trioleate, Sorbitanmonoerucat, Sorbitansesquierucat, Sorbitandierucat, Sorbitantrierucat, Sorbitanmonoricinoleat, Sorbitansesquiricinoleat, Sorbitandiricinoleat, Sorbitantriricinoleat, Sorbitanmonohydroxystearat, Sorbitansesquihydroxystearat, sorbitan tandihydroxystearat, Sorbitantrihydroxystearat, Sorbitanmonotartrat , Sorbitan sesquitarate, sorbitan ditartrate, sorbitan tritartrate, sorbitan monocitrate, sorbitan sesquicitrate, sorbitan dicitrate,
  • polyglycerol esters are polyglyceryl-2 dipolyhydroxystearates (Dehymuls® PGPH), polyglycerol-3-diisostearates (Lameform® TGI), polyglyceryl-4 isostearates (Isolan® GI 34), polyglyceryl-3 oleates, diisostearoyl polyglyceryl-3 dihydrogen - sostearate (Isolan® PDI), Polyglyceryl-3 Methylglucose Distearate (Tego Care® 450), Polyglyceryl-3 Beeswax (Cera Bellina®), Polyglyceryl-4 Caprate (Polyglycerol Caprate T2010 / 90), Polyglyceryl-3 Cetyl Ether (Chimexane® NL), Polyglyceryl-3 Distearate (Creophor® GS 32) and Polyglyceryl Polyricinoleate (Admul® WOL 1403) Polyglyceryl
  • polystyrene resin examples include the mono-, di- and triesters of trimethylolpropane or pentaerythritol with lauric acid, coconut fatty acid, taig fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and the like which are optionally reacted with 1 to 30 mol of ethylene oxide.
  • Typical anionic emulsifiers are aliphatic fatty acids with 12 to 22 carbon atoms, such as, for example, palmitic acid, stearic acid or behenic acid, and dicarboxylic acids with 12 to 22 carbon atoms, such as, for example, azelaic acid or sebacic acid.
  • Zwitterionic surfactants can also be used as emulsifiers.
  • Zwitterionic surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxylm -3-hydroxyethylimidazolines each with 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylam ⁇ noethylhydroxyethylcarboxymethylglycinat.
  • betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium g
  • Suitable emulsifiers are ampholytic surfactants.
  • Ampholytic surfactants are surface-active compounds which, apart from a C 8 i 8 alkyl or acyl group in the molecule / at least one free amino group and at least one -COOH or -SO3H group and are capable of forming inner salts.
  • ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each with about 8 to 18 carbon atoms in the alkyl group .
  • ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C 2 / i 8 acyl sarcosine.
  • cationic surfactants can also be used as emulsifiers, those of the ester quat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred.
  • Typical examples of fats are glycerides, i.e. Solid or liquid vegetable or animal products, which consist essentially of mixed glycerol esters of higher fatty acids, come as waxes, among others. natural waxes, e.g. Candelilla wax, carnauba wax, Japanese wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, walnut, lanolin (wool wax), pretzel fat, ceresin, ozokerite (earth wax), petrolatum, paraffin waxes, microfax waxes chemically modified waxes (hard waxes), e.g.
  • natural waxes e.g. Candelilla wax, carnauba wax, Japanese wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, ouricury wax, montan wax,
  • Montanester waxes Montanester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes, such as Polyalkylene waxes and polyethylene glycol waxes in question.
  • fat-like substances such as lecithins and phospholipids can also be used as additives.
  • lecithins as those glycerophospholipids which are formed from fatty acids, glycerol, phosphoric acid and choline by esterification. Lecithins are therefore often used in the professional world as phosphatidylcholines (PC).
  • Examples of natural lecithins are the cephalins, which are also referred to as phosphatidic acids and are derivatives of 1,2-diacyl-sn-glycerol-3-phosphoric acids.
  • phospholipids are usually understood to be mono- and preferably diesters of phosphoric acid with glycerol (glycerol phosphates), which are generally classed as fats.
  • glycerol phosphates glycerol phosphates
  • sphingosines or sphingolipids are also suitable.
  • Pearlescent waxes are: alkylene glycol esters, especially ethylene glycol stearate; Fatty acid alkanolamides, especially coconut fatty acid diethanolamide; Partial glycerides, especially stearic acid monoglyceride; Esters of polyvalent, optionally hydroxy-substituted carboxylic acids with fatty alcohols having 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; Fatty substances, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which have a total of at least 24 carbon atoms, especially lauron and distearyl ether; Fatty acids such as stearic acid, hydroxystearic acid or behenic acid, ring opening products of olefin epoxides with 12 to 22 carbon atoms with fatty alcohols with 12 to 22 carbon atoms and / or polyols with 2 to 15 carbon atoms
  • Suitable consistency agents are primarily fatty alcohols or hydroxy fatty alcohols with 12 to 22 and preferably 16 to 18 carbon atoms and, in addition, partial glycerides, fatty acids or hydroxy fatty acids.
  • a combination of these substances with alkyl oligoglucosides and / or fatty acid N-methylglucamides of the same chain length and / or polyglycerol poly-12-hydroxystearates is preferred.
  • Suitable thickeners are, for example, Aerosil types (hydrophilic silicas), polysaccharides, in particular xanthan gum, guar guar, agar agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl and hydroxypropyl cellulose, and also higher molecular weight polyethylene glycol mono- and diesters of fatty acids, Polyacrylates, (eg Carbopole® and Pemulen types from Goodrich; Synthalene® from Sigma; Keltrol types from Kelco; Sepigel types from Seppic; Salcare types from Allied Colloids), polyacrylamides, polymers, polyvinyl alcohol and polyvinyl pyrrolidone.
  • Aerosil types hydrophilic silicas
  • polysaccharides in particular xanthan gum, guar guar, agar agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl and hydroxypropyl cellulose,
  • Bentonites such as e.g. Bentone® Gel VS-5PC (Rheox), which is a mixture of cyclopentasiloxane, disteardimonium hectorite and propylene carbonate.
  • Surfactants such as, for example, ethoxylated fatty acid glycerides, esters of fatty acids with polyols such as, for example, pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with a narrow homolog distribution or alkyl oligoglucosides and electrolytes such as sodium chloride and ammonium chloride are also suitable.
  • Substances such as, for example, lanolin and lecithin and polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides can be used as superfatting agents, the latter simultaneously serving as foam stabilizers.
  • Metal salts of fatty acids such as magnesium, aluminum and / or zinc stearate or ricinoleate can be used as stabilizers.
  • Suitable cationic polymers are, for example, cationic cellulose derivatives, e.g. a quaternized hydroxyethyl cellulose available under the name Polymer JR 400® from Amerchol, cationic starch, copolymers of diallylammonium salts and acrylic amides, quaternized vinylpyrrolidone / vinylimidazole polymers such as e.g.
  • Luviquat® condensation products of polyglycols and amines, quaternized collagen polypeptides, such as, for example, lauryldimonium hydroxypropyl hydrolyzed collagen (Lamequat®L / Grünau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers, such as e.g. Amodimethicones, copolymers of adipic acid and dimethylaminohydroxypropyldiethylenetriamine (Cartaretine® / Sandoz), copolymers of acrylic acid with dimethyldiallylammonium chloride (Merquat® 550 / Chemviron), polyaminopolyamides, e.g.
  • cationic chitin derivatives such as quaternized chitosan, optionally microcrystalline, condensation products from dihaloalkylene, such as e.g. Dibromobutane with bisdialkylamines, e.g. Bis-dimethylamino-1,3-propane, cationic guar gum, e.g. Jaguar® CBS, Jaguar® C-17, Jaguar® C-16 from Celanese, quaternized ammonium salt polymers such as e.g. Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 from Miranol.
  • dihaloalkylene such as e.g. Dibromobutane with bisdialkylamines, e.g. Bis-dimethylamino-1,3-propane
  • cationic guar gum e.g. Jaguar® CBS, Jaguar® C-17, Jaguar® C-16 from Celanese
  • quaternized ammonium salt polymers such as e.g.
  • Anionic, zwitterionic, amphoteric and nonionic polymers include, for example, vinyl acetate / crotonic acid copolymers, vinylpyrrolidone / vinyl acrylate copolymers, vinyl acetate / butyl maleate / isobornyl acrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and polyesters and their esters, uncrosslinked , Acrylamido-propyltrimethylammonium chloride / acrylate copolymers, octylacrylamide / methyl methacrylate / tert-butylaminoethyl methacrylate / 2-hydroxypropyl methacrylate copolymers, polyvinyl pyrrolidone, vinyl pyrrolidone / vinyl acetate copolymers, vinyl pyrrolidone / teraminate / vinyl acrylate methacrylate / vinyl methacrylate methacrylate
  • Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenylpolysiloxanes, cyclic silicones and amino, fatty acid, alcohol, polyether, epoxy, fluorine, glycoside and / or alkyl modified silicone compounds which are both liquid and resinous at room temperature can.
  • simethicones which are mixtures of dimethicones with an average chain length of 200 to 300 dimethylsiloxane units and hydrogenated silicates.
  • UV light protection factors are understood to mean, for example, organic substances (light protection filters) which are liquid or crystalline at room temperature and which are able to absorb ultraviolet rays and absorb the energy absorbed in the form of longer-wave radiation, e.g. To give off heat again.
  • UVB filters can be oil-soluble or water-soluble. As oil-soluble substances e.g. to call:
  • 4-aminobenzoic acid derivatives preferably 2-ethyl-hexyl 4- (dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and amyl 4- (dimethylamino) benzoate;
  • esters of cinnamic acid preferably 2-ethylhexyl 4-methoxycinnamate, propyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate, 2-ethylhexyl 2-cyano-3,3-phenylcinnamate (octocrylene);
  • esters of salicylic acid preferably salicylic acid 2-ethylhexyl ester, salicylic acid 4-isopropylbenzyl ester, salicylic acid homomethyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4 ⁇ - methylbenzophenone, 2,2 , -dihydroxy-4-methoxybenzophenone;
  • esters of benzalmalonic acid preferably 4-methoxybenzmalonic acid di-2-ethylhexyl ester;
  • Triazine derivatives such as 2,4,6-trianilino- (p-carbo-2 ⁇ -ethyl-f-hexyloxy) -l, 3,5-triazine and octyl triazone, as described in EP 0818450 AI or dioctyl butamido triazone (Uvasorb® HEB);
  • Propane-1,3-diones such as 1- (4-tert-butylphenyl) -3- (4 , methoxyphenyl) propane-1,3-dione;
  • Typical UV-A filters are, in particular, derivatives of benzoyl methane such as l- (4, -tert.Butylphenyl) -3- (4-methoxyphenyl) propan-l, 3-dione, 4-tert-butyl -4 l - methoxydibenzoylmethane (Parsol® 1789), l-phenyl-3- (4 sopropylphenyl) propane-l, 3-dione and enamine compounds, as described in DE 19712033 AI (BASF).
  • the UV-A and UV-B filters can of course also be used in mixtures.
  • Particularly favorable combinations consist of the derivatives of benzoylmethane, for example 4-tert-butyl-4 , -methoxydibenzoylmethane (Parsol® 1789) and 2-cyano-3,3-phenylcinnamic acid-2-ethyl-hexyl ester (octocrylene) in combination with Esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate and / or propyl 4-methoxycinnamate and / or isoamyl 4-methoxycinnamate.
  • benzoylmethane for example 4-tert-butyl-4 , -methoxydibenzoylmethane (Parsol® 1789) and 2-cyano-3,3-phenylcinnamic acid-2-ethyl-hexyl ester (octocrylene) in combination with Esters of cinnamic acid, preferably 2-eth
  • water-soluble filters such as 2-phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammonium, alkylammonium, alkanolammonium and glucammonium salts.
  • insoluble light protection pigments namely finely dispersed metal oxides or salts
  • suitable metal oxides are, in particular, zinc oxide and titanium dioxide and, in addition, oxides of iron, zirconium, silicon, manganese, aluminum and cerium and mixtures thereof.
  • Silicates (talc), barium sulfate or zinc stearate can be used as salts.
  • the oxides and salts are used in the form of the pigments for skin-care and skin-protecting emulsions and decorative cosmetics.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm.
  • the pigments can also be surface-treated, ie hydrophilized or hydrophobicized.
  • Typical examples are coated titanium dioxides, such as titanium dioxide T 805 (Degussa) or Eusolex® T2000 (Merck). Silicones, and in particular trialkoxyoctylsilanes or simethicones, are particularly suitable as hydrophobic coating agents. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used.
  • UV protection filters are in the overview by P.Finkel in S ⁇ FW-Journal 122, 543 (1996) and Parf.Kosm. 3, 11 (1999).
  • secondary light stabilizers of the antioxidant type can also be used, which interrupt the photochemical reaction chain which is triggered when UV radiation penetrates the skin.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g.
  • carotenoids e.g. cc-carotene, ß-carotene, lycopene
  • carotenes e.g. cc-carotene, ß-carotene, lycopene
  • chlorogenic acid and their derivatives e.g. dihydroliponic acid
  • lipoic acid and their derivatives e.g. dihydroliponic acid
  • aurothioglucose e.g.
  • thioredoxin Glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters ) as well as their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthioninsulfoximines, homocysteine sulfoximine, butioninsulfones, pentathion, hexa-, hexa-, heptoximine geri compatible doses (e.g.
  • (metal) chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin , Biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. ⁇ -linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g.
  • biogenic active ingredients are tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, (deoxy) ribonucleic acid and its fragmentation products, ⁇ -glucans, retinol, bisabolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudo-ceramides, petition ceramides, To understand plant extracts such as prunus extract, Bambaranus extract and vitamin complexes. Deodorants and germ inhibitors
  • Cosmetic deodorants counteract, mask or eliminate body odors.
  • Body odors arise from the action of skin bacteria on apocrine sweat, whereby unpleasant smelling breakdown products are formed. Accordingly, deodorants contain active ingredients which act as germ-inhibiting agents, enzyme inhibitors, odor absorbers or odor maskers.
  • germ-inhibiting agents such as.
  • Esterase inhibitors are suitable as enzyme inhibitors. These are preferably trialkyl citrates such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and in particular triethyl citrate (Hydagen® CAT).
  • the substances inhibit enzyme activity and thereby reduce odor.
  • esterase inhibitors include sterol sulfates or phosphates, such as, for example, lanosterol, cholesterol, campesteric, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and their esters, such as, for example, glutaric acid, glutaric acid monoethyl ester, glutaric acid diethyl ester, Adipic acid, adipic acid monoethyl ester, adipic acid diethyl ester, malonic acid and malonic acid diethyl ester, hydroxycarboxylic acids and their esters such as citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.
  • odor absorbers such as citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.
  • Suitable odor absorbers are substances that absorb odor-forming compounds and can retain them to a large extent. They lower the partial pressure of the individual components and thus also reduce their speed of propagation. It is important that perfumes must remain unaffected. Odor absorbers are not effective against bacteria. They contain, for example, a complex zinc salt of ricinoleic acid or special, largely odorless fragrances, which are known to the person skilled in the art as "fixators", such as, for example, the main component. B. extracts of Labdanum or Styrax or certain abietic acid derivatives. Fragrance agents or perfume oils act as odor maskers and, in addition to their function as odor maskers, give the deodorants their respective fragrance.
  • Perfume oils are, for example, mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers, stems and leaves, fruits, fruit peels, roots, woods, herbs and grasses, needles and branches as well as resins and balms. Animal raw materials, such as civet and castoreum, are also suitable. Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type.
  • Fragrance compounds of the ester type are, for example, benzyl acetate, p-tert-butylcyclohexyl acetate, linalyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, allyl cyclohexyl propionate, styrallyl propionate and benzyl salicylate.
  • the ethers include, for example, benzyl ethyl ether
  • the aldehydes include, for example, the linear alkanals having 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamenaldehyde, hydroxycitronellal, lilial and bourgeonal
  • the ketones include, for example, the joonones and methylcedryl ketone
  • the alcohols are anethole
  • Citronellol Citronellol
  • eugenol isoeugenol
  • geraniol linalool
  • the hydrocarbons mainly include the terpenes and balsams.
  • fragrance oils of lower volatility which are mostly used as aroma components, are also suitable as perfume oils, for example sage oil, chamomile oil, clove oil, lemon balm oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbane oil, labdanum oil and lavandin oil.
  • Antiperspirants reduce sweat formation by influencing the activity of the eccrine sweat glands and thus counteract armpit wetness and body odor.
  • Aqueous or anhydrous formulations of antiperspirants typically contain the following ingredients:
  • non-aqueous solvents such as As ethanol, propylene glycol and / or glycerin.
  • Salts of aluminum, zirconium or zinc are particularly suitable as astringent antiperspirant active ingredients.
  • suitable antiperspirant active ingredients are e.g. Aluminum chloride, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate and their complex compounds z. B. with propylene glycol-1,2.
  • customary oil-soluble and water-soluble auxiliaries can be present in smaller amounts in antiperspirants.
  • Such oil soluble aids can e.g. his:
  • Usual water-soluble additives are, for example, preservatives, water-soluble fragrances, pH adjusting agents, for example buffer mixtures, water-soluble thickeners, for example water-soluble natural or synthetic polymers such as, for example, xanthan gum, hydroxyethyl cellulose, polyvinyl pyrrolidone or high molecular weight polyethylene oxides. film formers
  • Common film formers are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid or its salts and similar compounds.
  • Montmorillonites, clay minerals, pemulene and alkyl-modified carbopol types can serve as swelling agents for aqueous phases. Further suitable polymers or swelling agents can be found in the overview by R. Lochhead in Cosm.Toil. 108, 95 (1993).
  • Possible insect repellents are N, N-diethyl-m-toluamide, 1,2-pentanediol or ethyl butyl acetylaminopropionate
  • Dihydroxyacetone is suitable as a self-tanner.
  • Arbutin, ferulic acid, kojic acid, coumaric acid and ascorbic acid (vitamin C) can be used as tyrosine inhibitors, which prevent the formation of melanin and are used in depigmenting agents.
  • Hydrotropes such as ethanol, isopropyl alcohol or polyols can also be used to improve the flow behavior.
  • Polyols that come into consideration here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups.
  • the polyols can also contain further functional groups, in particular amino groups, or be modified with nitrogen. Typical examples are >Glycerin;
  • Alkylene glycols such as, for example, ethylene glycol, diethylene glycol, propylene glycol, butylene glycol, hexylene glycol and polyethylene glycols with an average molecular weight of 100 to 1,000 daltons;
  • Methyl compounds such as, in particular, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol;
  • Dialcohol amines such as diethanolamine or 2-amino-l, 3-propanediol.
  • Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid, as well as the silver complexes known under the name Surfacine® and the other classes of substances listed in Appendix 6, Parts A and B of the Cosmetics Ordinance.
  • Perfume oils include mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers (lily, lavender, roses, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, cumin, juniper), fruit peel (bergamot, lemon, Oranges), roots (mace, angelica, celery, cardamom, costus, iris, calmus), woods (pine, sandal, guaiac, cedar, rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme) ), Needles and twigs (spruce, fir, pine, mountain pine), resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opoponax).
  • Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type. Fragrance compounds of the ester type are, for example, benzyl acetate, phenoxyethyl isobutyrate, p-tert.- Butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinylacetate, phenylethyl acetate, linylbenzoate, benzyl formate, ethylmethylphenylglycinate, allylcyclohexylpropionate, styrallylpropionate and benzylsalicylate.
  • the ethers include, for example, benzyl ethyl ether, the aldehydes, for example, the linear alkanals having 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamenaldehyde, hydroxycitronellal, lilial and bourgeonal, the ketones, for example, the jonones, ⁇ -isomethyl ionone and methyl cedryl ketone , the alcohols anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol, the hydrocarbons mainly include the terpenes and balsams.
  • fragrance oils which are mostly used as aroma components, are also suitable as perfume oils, e.g. sage oil, chamomile oil, clove oil, lemon balm oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbanum oil, labolanum oil and lavandin oil.
  • Suitable flavors are, for example, peppermint oil, spearmint oil, anise oil, star anise oil, cumin oil, eucalyptus oil, fennel oil, lemon oil, winter green oil, clove oil, menthol and the like.
  • the dyes which can be used are those substances which are suitable and approved for cosmetic purposes, as compiled, for example, in the publication "Cosmetic Dyes” by the Dye Commission of the German Research Foundation, Verlag Chemie, Weinheim, 1984, pp. 81-106. Examples are culinary red A (CI 16255), patent blue V (CI42051), indigo (CI73015), chlorophyllin (CI75810), quinoline yellow (CI47005), titanium dioxide (CI77891), indanthrene blue RS (CI 69800) and madder varnish (CI58000). Luminol may also be present as the luminescent dye. These dyes are usually used in concentrations of 0.001 to 0.1% by weight, based on the mixture as a whole. The total proportion of auxiliaries and additives can be 1 to 50, preferably 5 to 40,% by weight, based on the composition.
  • the agents can be produced by customary cold or hot processes; the phase inversion temperature method is preferably used.
  • Production Example 1 0.05 kg of finely chopped chicory roots were placed in a beaker with 500 ml of 70% by volume aqueous methanol. The mixture was stirred at 45 ° C for one hour and the solid components were filtered off. Thereafter, the extract was freed from the methanol and freeze-dried, whereby a residue of 18.6 g was obtained. 10 g of this crude extract were taken up in 10 ml of water, placed on a 4 x 40 cm Amberlite XAD 1180 column and successively with 750 ml of water, 750 ml of methanol (40% by volume) and 3750 ml of methanol (60% by volume) %) eluted. In addition to chicory acid, the eluate mainly contained chlorogenic acid, free caffeic acid and various coffee yl conjugates.
  • Production Example 2 16 kg of powdered chicory roots were placed in a beaker with 78 liters of 96% by volume ethanol. The mixture was stirred at 45 ° C. for 6 hours and the solid constituents were filtered off. The ethanol was then evaporated from the filtered solution until a dry extract with a concentration of 23% by weight (23 g dry extract per 100 ml liquid) was obtained.
  • the crude extract was placed on a conditioned 50 mm x 250 mm Lichrosher RP18-lO ⁇ m HPLC column and eluted with an eluant from 76% water, 4% acetic acid and 20% acetonitrile. The peak after 900 to 1000 seconds was collected. The eluent was removed by evaporation and the fraction sought was obtained by freeze-drying.
  • UVB was chosen as a stress factor because the rays cause cutaneous inflammation (erythema, edema) by activating arachidonic acid-releasing enzymes, such as phospholipase A2 (PLA2).
  • PHA2 phospholipase A2
  • UV-B rays on the keratinocytes was determined in vitro via the release of cytoplasmic enzymes, such as LDH (lactate dehydrogenase), which runs parallel to cell damage and the formation of PGE2.
  • a fibroblast culture with fetal calf serum was set up and vaccinated with the test substances 2 days later. After an incubation of 36 h at 37 ° C and a CO 2 level of 5% by volume, the nutrient medium was replaced by an electrolyte solution and the fibroblasts were damaged with a defined amount of UVB radiation (50 mJ / cm 2 ). After trypsination, the amount of keratinocytes was determined using a cell counter, and the LDH concentration was determined enzymatically. The results are summarized in Table 1. The activity is given in% -rel against a standard as the mean of two test series with double determination.
  • a commercial skin cream was mixed with a content of 4 ⁇ l of a 1.5% by weight aqueous solution of the extract according to the preparation example. Then, in a panel consisting of 10 test subjects, an area of 1 cm 2 on each inner side of the forearm was treated with 3 ⁇ l of a 70% by weight glycolic acid solution. Then, on the right forearm, the test cream was applied to the left forearm, on the other hand, a placebo cream, although the test subjects naturally did not know which cream contained the ingredient to be tested. The extent of the irritation was assessed as a function on a scale from 0 (none) to 3 (clearly) over an exposure period of 10 min. The results (mean values) are summarized in Table 2. The average of the stimulus scores for the placebo was 2.75 and for the test substance 0.2.
  • leucocytes such as the polymorphonuclear neutrophil granulocytes (PMN)
  • PMN polymorphonuclear neutrophil granulocytes
  • peptides such as cytokines to emit messenger substances such as leukotriene, which are released in the dermis by activated or necrotic cells.
  • ROS such as superoxides and hypochlorite anions, which have the task of destroying invaded pathogenic germs or fungi.
  • This activity of the PMN during inflammation is known as a so-called respiratory burst and can lead to additional damage. lead in the tissue.
  • chicory extract has a strong inhibitory effect on the respiratory outbreak of human granuloctyes without damaging them.
  • Free radicals are a reactive species, characterized by non-conjugated free electrons. They result, for example, from unsaturated fatty acids, certain amino acids and above all oxygen, which is formed spontaneously during biological processes, such as in the respiratory chain in mitochondria or during natural inflammatory processes. Oxidative stress such as UV radiation or environmental toxins induce the formation of free radicals, which then cause damage to the cells and tissue components (lipids, proteins, sugars and nucleic acids). In fact, the toxicity of free radicals is decisively influenced by the oxygen content and plays an essential role in the aging process and in serious diseases such as cancer and diabetes.
  • the activity against free radicals was determined by a biochemical test with a reactive oxygen species (ROS), the so-called superoxide anion (O2 °).
  • Superoxide anions come from xanthine oxidase and lipoxygenase activities.
  • Xanthine oxidase (XOD) is an enzyme that is activated during oxidative stress and catalyzes the O2 ° release during the degradation of hypoxanthine (HX), which is produced in excess in the event of a disturbance in the energetic cell metabolism.
  • HX hypoxanthine
  • 02 ° is then converted spontaneously or by superoxide dismutase (SOD) into hydrogen peroxide (H2O2), which in turn forms a source for HO radicals that continue to react in the Fenton reaction.
  • G6PDH glucose-6-phosphate dehydrogenase
  • the deoxyribose an essential component of DANN is produced: the deoxyribose.
  • Reduced glutathione can protect skin enzymes with SH groups or strengthen the viability of cells against oxidative stress. Therefore G6PDH is an important enzyme for skin renewal and synthesis of important components Protection of cells against oxidative stress.
  • the G6PDH activity (glucose 6 phosphate dehydrogenase) was determined according to that of Garidelli de Quincenet in Annual Dermatol.Venereoi. 107 (12). 1163-1170 (1980).
  • the DNA content was determined according to the method described by Desaulniers in Toxicln vitro 12f4 409-422 (1998) on in vitro cultures of human dermal fibroblasts. The incubation period of the fibroblasts was 3 days each. The results are summarized in Table 1. The average of 8 experiments in triplicate is given.
  • Table 5 G6PDH activity - determination on human dermal fibroblasts
  • the investigated chicory root extract as well as the retinoic acid have significantly increased the G ⁇ PDH activity in human fibroblasts and thus have a high potential to stimulate cells in the fight against oxidative stress and environmental toxins and to maintain vital components of the skin such as collagen, elastin and glycoproteins and renew.
  • Tables 6 a and b contain a number of formulation examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des agents cosmétiques se caractérisant par une teneur active en au moins un ester d'acide caféique.
EP02771566A 2001-05-21 2002-05-11 Agents cosmetiques Withdrawn EP1487400A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02771566A EP1487400A2 (fr) 2001-05-21 2002-05-11 Agents cosmetiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01401318A EP1260212A1 (fr) 2001-05-21 2001-05-21 Composition cosmetique
EP01401318 2001-05-21
PCT/EP2002/005201 WO2002094210A2 (fr) 2001-05-21 2002-05-11 Agents cosmetiques
EP02771566A EP1487400A2 (fr) 2001-05-21 2002-05-11 Agents cosmetiques

Publications (1)

Publication Number Publication Date
EP1487400A2 true EP1487400A2 (fr) 2004-12-22

Family

ID=8182734

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01401318A Withdrawn EP1260212A1 (fr) 2001-05-21 2001-05-21 Composition cosmetique
EP02771566A Withdrawn EP1487400A2 (fr) 2001-05-21 2002-05-11 Agents cosmetiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01401318A Withdrawn EP1260212A1 (fr) 2001-05-21 2001-05-21 Composition cosmetique

Country Status (6)

Country Link
US (1) US20040170581A1 (fr)
EP (2) EP1260212A1 (fr)
JP (1) JP2005506310A (fr)
KR (1) KR20040021604A (fr)
AU (1) AU2002338914A1 (fr)
WO (1) WO2002094210A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532852T3 (es) * 2002-06-26 2015-04-01 Nestec S.A. Extracto de café extruido para su uso en el tratamiento de la osteoartritis
JP2005053891A (ja) * 2003-07-18 2005-03-03 Seresu Corporation:Kk リパーゼ阻害剤
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
SI1591105T1 (sl) 2004-03-17 2020-09-30 Stada Arzneimittel Ag Uporaba antioksidantov za pripravo farmacevtskega ali kozmetičnega sestavka za zaščito kože pred poškodbo z infrardečim sevanjem
DE602005023447D1 (de) 2004-06-15 2010-10-21 Boots Co Ltd Haarpflegezusammensetzungen und verfahren
FR2877572B1 (fr) * 2004-11-10 2008-03-21 Claude Bonne Nouvelles compositions pharmaceutiques, alimentaires ou cosmetiques pour prevenir et traiter l'acne
WO2006127525A2 (fr) * 2005-05-20 2006-11-30 Jack Arbiser Inhibiteurs de proteasome et utilisations de ceux-ci
US7226623B2 (en) * 2005-10-31 2007-06-05 Rutgers, The State University Of New Jersey In vitro and in vivo anti-inflammatory effects of a sesquiterpene lactone extract from chicory (Cichorium intybus L.)
JP4713324B2 (ja) * 2005-12-13 2011-06-29 ユーシーシー上島珈琲株式会社 ヒアルロニダーゼ阻害剤
KR100760246B1 (ko) * 2006-02-28 2007-09-21 주식회사 비젼에이드 휴대용 엘씨디(lcd) 독서기
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
KR100871911B1 (ko) * 2007-05-23 2008-12-05 주식회사 엘지생활건강 자외선 차단 화장료 조성물
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
JP2010070496A (ja) * 2008-09-18 2010-04-02 Tsumura Lifescience Co Ltd 毛髪および／または毛包強化因子産生促進剤
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
DE102009044973A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung eines Wirkstoffes aus Echinacea zur Beeinflussung des natürlichen Pigmentierungsprozesses
AU2010297406B2 (en) 2009-09-24 2013-10-17 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
FR2953725B1 (fr) 2009-12-15 2015-10-23 Natura Cosmeticos Sa Procede pour obtenir un extrait standardise de quercetine et de 3-o-methylquercetine a partir d'inflorescences de macela-do-campo, et composition cosmetique, pharmaceutique et veterinaire le contenant
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CA2803461C (fr) 2010-06-30 2018-09-25 Nestec S.A. Utilisation de l'acide caftarique et ses derives dans un complement alimentaire pour reguler la pigmentation de la peau
CN103025307B (zh) * 2010-06-30 2017-03-29 雀巢产品技术援助有限公司 菊苣酸及衍生物用于调节皮肤色素沉着的用途
WO2012076310A1 (fr) 2010-12-07 2012-06-14 Unilever Nv Composition de soin buccal
ITCS20110009A1 (it) 2011-03-21 2012-09-22 Univ Calabria Formulazione cosmetica, farmaceutica o nutraceutica contenente molecole antiossidanti coniugate
CA2832324C (fr) 2011-04-04 2022-03-15 Berg Llc Methodes de traitement de tumeurs du systeme nerveux central
EP2720680B1 (fr) 2011-06-17 2020-02-12 Berg LLC Compositions pharmaceutiques inhalables
KR20170012588A (ko) * 2011-10-11 2017-02-02 이엘씨 매니지먼트 엘엘씨 피부를 처리하기 위한 방법 및 조성물
MX2014005405A (es) 2011-11-03 2014-06-23 Unilever Nv Una composicion de limpieza personal.
KR101373714B1 (ko) * 2012-04-26 2014-03-13 엔프라니 주식회사 각화막 형성 촉진용 화장료 조성물
CN104797237B (zh) * 2012-09-14 2020-11-24 Elc 管理有限责任公司 用于改善角蛋白表面的细胞中的选择性分解代谢的方法和组合物
US10383815B2 (en) 2012-09-14 2019-08-20 Elc Management Llc Method and compositions for improving selective catabolysis in cells of keratin surfaces
KR101458060B1 (ko) * 2013-01-12 2014-11-04 한국세라믹기술원 카페인산에스테르 함유 항균 골충진 조성물 및 이의 제조방법
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
EP2848286A1 (fr) * 2013-09-12 2015-03-18 DSM IP Assets B.V. Composition cosmétique comprenant de l'acide chicorique
JP5732641B2 (ja) * 2013-09-17 2015-06-10 株式会社バスクリン 肝細胞増殖因子産生促進剤
KR101409111B1 (ko) * 2013-12-02 2014-06-17 스킨큐어(주) 카페산 또는 이의 염을 포함하는 여드름 치료 또는 예방용 조성물
WO2017087576A1 (fr) 2015-11-16 2017-05-26 Berg Llc Procédés de traitement de gliome résistant au témozolomide utilisant la coenzyme q10
FR3047171A1 (fr) 2016-01-29 2017-08-04 Plant Advanced Tech Pat Esters de dipropylene glycol des acides dicafeoylquiniques, extrait vegetal les contenant, procede d'obtention et utilisations
KR102475130B1 (ko) * 2016-03-31 2022-12-07 (주)아모레퍼시픽 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물
FR3050455B1 (fr) * 2016-04-26 2019-06-14 Temisis Derives amides des acides polycafeoylquiniques, procede de preparation et utilisations
JP6522552B2 (ja) * 2016-06-17 2019-05-29 イーエルシー マネージメント エルエルシー 皮膚を処理するための方法および組成物
CN110151625A (zh) * 2016-08-24 2019-08-23 田中荣 一种适用于全身皮肤的具有保湿修护作用的化妆用组合物
EP3375433B1 (fr) * 2017-03-16 2020-02-19 Chanel Parfums Beauté Composition cosmétique comprenant un extrait de menthe poivrée
FR3080032B1 (fr) * 2018-04-13 2020-04-17 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Utilisation d'une nouvelle composition pour empecher ou ralentir l'apparition de signes d'inflammation
KR102084261B1 (ko) * 2019-02-25 2020-03-03 김능수 문신용 염료조성물 및 그 제조방법
JP7612326B2 (ja) * 2019-12-16 2025-01-14 ロレアル 特定の成分の組合せを含む安定な組成物
JP2021143131A (ja) * 2020-03-10 2021-09-24 丸善製薬株式会社 抗老化剤、皮膚化粧料および経口組成物
TWI821584B (zh) * 2020-07-16 2023-11-11 嘉年生化產品有限公司 新穎抗發炎化合物，其製法及其應用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779645A1 (fr) * 1998-06-11 1999-12-17 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un melange d'extrait de cafe vert et de beurre de karite

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7804290A (nl) * 1977-05-12 1978-11-14 Henkel Kgaa Ontsteking vertragend middel voor cosmetische prepara- ten.
AU2300588A (en) * 1987-08-04 1989-03-01 Trustees Of Columbia University In The City Of New York, The Caffeic acid esters and method of preparing and using same
FR2626469B1 (fr) * 1988-01-29 1990-07-20 Diot Michel Nouvelles preparations cosmetiques contenant un extrait des parties aeriennes de cichorium intybus l
FR2652001B1 (fr) * 1989-09-20 1994-09-09 Andary Claude Composition dermato-cosmetique a base d'acide rosmarinique presentant des proprietes de filtre solaire et d'agent anti-inflammatoire.
FR2653336B1 (fr) * 1989-10-20 1994-04-08 Oreal Composition pharmaceutique et cosmetiques depigmentantes a base d'acide cafeique.
AU670742B2 (en) * 1991-03-21 1996-08-01 Parfums Christian Dior Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it
FR2693105B1 (fr) * 1992-07-01 1994-09-02 Oreal Composition cosmétique et/ou dermatologique à action dépigmentante contenant un acide di- ou tri-caféoylquinique ou un mélange de ceux-ci.
US5443844A (en) * 1992-12-03 1995-08-22 Mcdaniel; William R. Linoleic acid preparations for topical treatment of acne vulgaris
FR2699818B1 (fr) * 1992-12-24 1995-02-03 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
JPH08301721A (ja) * 1995-05-09 1996-11-19 Pola Chem Ind Inc 皮膚化粧料
FR2734479B1 (fr) * 1995-05-23 1997-07-11 Berkem Sa Preparation d'un extrait vegetal ayant des proprietes d'ecran total vis-a-vis des uv, extrait vegetal obtenu, son utilisation et composition cosmetique ou pharmaceutique contenant ledit extrait
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6306443B1 (en) * 2000-06-20 2001-10-23 Amway Corporation Method of increasing concentrations of caffeic acid derivatives and alkylamides and compositions containing the same
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779645A1 (fr) * 1998-06-11 1999-12-17 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un melange d'extrait de cafe vert et de beurre de karite

Also Published As

Publication number Publication date
US20040170581A1 (en) 2004-09-02
KR20040021604A (ko) 2004-03-10
WO2002094210A2 (fr) 2002-11-28
AU2002338914A1 (en) 2002-12-03
EP1260212A1 (fr) 2002-11-27
WO2002094210A3 (fr) 2004-10-21
JP2005506310A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
EP1392237B1 (fr) Preparations cosmetiques contenant un extrait de seigle germant
EP1487400A2 (fr) Agents cosmetiques
EP1303255B1 (fr) L'utilisation d'une composition inhibant la croissance pileuse
EP1284133B1 (fr) Mélanges de principes actifs
EP1372685B1 (fr) Utilisation d'extraits de la plante litchi chinensis sonn.
EP1340486A1 (fr) Utilisation d' esters de sucre
EP1339421B1 (fr) Preparations cosmetiques ou dermopharmaceutiques contenant des proteines natives de la plante argania spinosa
EP1385473A1 (fr) Utilisation de procyanolidines oligomeres
EP1239826A2 (fr) Preparations cosmetiques et/ou pharmaceutiques
EP1351662A1 (fr) Preparations cosmetiques et/ou pharmaceutiques
EP1170015A1 (fr) Utilisation des extraits du champignon Grifola frondosa
EP1441747B1 (fr) Utilisation d'un extrait de plante dite vigna aconitfolia dans une composition cosmetique et/ou dermopharmaceutique
EP1145709A1 (fr) Utilisation de produits naturels pour préparer des compositions cosmétiques
EP1253906B1 (fr) Preparations cosmetiques contenant des extraits de waltheria indica et de l'acide ferulique
EP1440683A1 (fr) Utilisation des oligoglucosamines dans des compositions cosmétiques ou dermatologiques
EP1596816A2 (fr) Preparations contenant un extrait d' i eperua falcata /i et/ou ses substances constitutives
WO2003043595A1 (fr) Agents anti-vieillissement
WO2003070152A2 (fr) Agents anti-vieillissement
WO2001052809A1 (fr) Preparations cosmetiques ou pharmaceutiques contenant une quantite efficace d'un extrait d'arrabidaea chica
EP1511714A1 (fr) Preparations cosmetiques et/ou pharmaceutiques a base d'esters de retinol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE ES FR GB IT LI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COGNIS FRANCE, S.A.S.

17Q First examination report despatched

Effective date: 20070209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081105